Royal Bank of Canada
CERE

Royal Bank of Canada’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Royal Bank of Canada’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,020
Closed -$164K – 7712
2024
Q2 		$164K Buy
4,020
+1,376
+52% +$57.3K ﹤0.01% 4918
2024
Q1 		$113K Sell
2,644
-19,985
-88% -$839K ﹤0.01% 5122
2023
Q4 		$959K Buy
22,629
+14,672
+184% +$422K ﹤0.01% 3698
2023
Q3 		$173K Buy
7,957
+3,907
+96% +$97.8K ﹤0.01% 4936
2023
Q2 		$128K Buy
4,050
+636
+19% +$19.5K ﹤0.01% 5134
2023
Q1 		$83K Sell
3,414
-4,736
-58% -$139K ﹤0.01% 5326
2022
Q4 		$257K Buy
8,150
+5,191
+175% +$146K ﹤0.01% 4668
2022
Q3 		$83K Buy
2,959
+480
+19% +$14.3K ﹤0.01% 5440
2022
Q2 		$66K Sell
2,479
-2,194
-47% -$62.3K ﹤0.01% 5591
2022
Q1 		$164K Sell
4,673
-14,305
-75% -$418K ﹤0.01% 5264
2021
Q4 		$615K Buy
18,978
+13,552
+250% +$478K ﹤0.01% 4288
2021
Q3 		$160K Buy
5,426
+3,012
+125% +$84.6K ﹤0.01% 5360
2021
Q2 		$62K Buy
+2,414
New +$34.6K ﹤0.01% 5900

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Royal Bank of Canada's CERE Position: Q3 2024 in Review

Royal Bank of Canada sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4,020 shares — an estimated $164K sold.

Royal Bank of Canada first reported a position in CERE in Q2 2021 and held it in 13 quarters. The position peaked at $959K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Royal Bank of Canada reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 4,020 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $164K.
  • Royal Bank of Canada first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Royal Bank of Canada's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $959K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.